Company profile
CHEMOMAB THERAPEUTICS LTD.
NASDAQ:CMMBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NEBOKITUG | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05824156 | phase2 | completed | 2021-02-24 | 2022-08-15 | ChemomAb Ltd. | CM-101 in NASH Patients - The SPLASH Study |
| NCT04595825 | phase2 | completed | 2020-10-01 | 2025-01-10 | ChemomAb Ltd. | CM-101 in PSC Patients -The SPRING Study |
| NCT06025851 | phase1 | completed | 2017-07-24 | 2018-02-18 | ChemomAb Ltd. | Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects |
| NCT06210945 | phase2 | suspended | 2026-09-01 | 2028-06-01 | ChemomAb Ltd. | Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis |
| NCT06037577 | phase1 | completed | 2019-03-05 | 2019-05-05 | ChemomAb Ltd. | Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects |
FDA applications (0)
No records yet.